马德里——阿斯利康（AZN，股价下跌1.20%）正准备提交其新一组合靶向抗癌药物中的首款产品以申请监管批准，旨在巩固其在肿瘤学市场增长最快的细分领域之一中的地位。
MADRID—AstraZeneca AZN -1.20%decrease; down pointing triangle is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.
通过与日本第一三共的联盟，阿斯利康一直处于最新一代称为抗体偶联药物（ADC）的药物类别的前沿，这类药物旨在通过直接用毒性药物打击肿瘤来取代标准化疗。但这家英国药企目前正在开发自主研发的产品线。
Through its alliance with Japan’s Daiichi Sankyo, AstraZeneca has been at the forefront of the latest generation of a class of medicines known as antibody-drug conjugates, or ADCs, which aim to replace standard chemotherapy by striking tumors directly with a toxic agent. But the U.K. drugmaker is now developing an in-house lineup.